← 返回

整合性 bulk 和单细胞转录组分析鉴定胶质瘤的核心基因网络和潜在治疗靶点

英文原题:Integrative bulk and single-cell transcriptomic profiling identifies core gene networks and potential therapeutic targets in glioma.

查看英文原题

Integrative bulk and single-cell transcriptomic profiling identifies core gene networks and potential therapeutic targets in glioma.

PubMed 2025/12/13(内容时间) BMC Cancer Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

六个已识别的枢纽基因在胶质瘤中一致下调,并展现出强大的诊断潜力。它们与免疫微环境和肿瘤细胞谱系的密切关联,凸显了其作为生物标志物和潜在治疗靶点的价值。

研究思路结论见上方概要

胶质瘤是中枢神经系统最常见的原发性恶性肿瘤,预后极差。鉴于其高度复杂的分子特征,迫切需要寻找新的诊断生物标志物。本研究通过多队列整合和单细胞分析,系统鉴定了胶质瘤核心基因。

整合了五个基因表达综合数据库(GEO)转录组数据集(GSE109857、GSE15824、GSE35158、GSE4290和GSE90886;504个样本),并使用ComBat校正批次效应。鉴定差异表达基因(DEGs),并结合加权基因共表达网络分析(WGCNA)获得候选模块。进一步使用多种方法筛选特征基因,包括CytoHubba、最小绝对收缩和选择算子(LASSO)回归、支持向量机-递归特征消除(SVM-RFE)和随机森林(RF)分析。使用外部GEO数据集、受试者工作特征(ROC)分析以及基于69个临床样本的定量实时聚合酶链反应(qRT-PCR)进行验证。其他分析包括基因集富集分析(GSEA)、基于CIBERSORT的免疫浸润分析、在三个单细胞RNA测序(scRNA-seq)数据集(GSE273274、GSE162631和GSE182109)中的表达映射,以及竞争性内源RNA(ceRNA)和转录因子(TF)网络的构建,还有药物富集分析。

共鉴定出409个与胶质瘤相关的候选基因。通过所有算法一致识别出6个枢纽基因:SYP、SYN1、RAB3A、SLC17A7、SYN2和STXBP1。GEO数据集(AUC:0.787-0.802)和临床qRT-PCR验证证实,这6个基因在胶质瘤中均显著下调。GSEA显示,这些基因的低表达与细胞周期激活、补体和凝血级联反应以及免疫失调相关。免疫浸润分析显示与M1/M2巨噬细胞和活化自然杀伤(NK)细胞呈负相关。单细胞分析表明,这些枢纽基因主要富集于肿瘤增殖细胞(TPC)样肿瘤细胞中,但在胶质瘤核心区域显著减少。竞争性内源RNA(ceRNA)/TF网络和药物富集分析提示存在多层调控机制以及与神经递质相关化合物的关联。

展开英文摘要原文

Glioma is the most common primary malignant tumor of the central nervous system and is associated with an extremely poor prognosis. Given its highly complex molecular landscape, there is an urgent need to identify novel diagnostic biomarkers. This study systematically identified core glioma genes through multi-cohort integration and single-cell analysis.

Five Gene Expression Omnibus (GEO) transcriptomic datasets (GSE109857, GSE15824, GSE35158, GSE4290, and GSE90886; 504 samples) were integrated, and batch effects were corrected using ComBat. Differentially expressed genes (DEGs) were identified and combined with weighted gene co-expression network analysis (WGCNA) to obtain candidate modules. Feature genes were further screened using multiple approaches, including CytoHubba, least absolute shrinkage and selection operator (LASSO) regression, support vector machine-recursive feature elimination (SVM-RFE), and random forest (RF) analysis. Validation was performed using external GEO datasets, receiver operating characteristic (ROC) analysis, and quantitative real-time polymerase chain reaction (qRT-PCR) based on 69 clinical samples. Additional analyses included gene set enrichment analysis (GSEA), CIBERSORT-based immune infiltration profiling, expression mapping across three single-cell RNA sequencing (scRNA-seq) datasets (GSE273274, GSE162631, and GSE182109), and construction of competing endogenous RNA (ceRNA) and transcription factor (TF) networks, as well as drug enrichment analysis.

A total of 409 glioma-related candidate genes were identified. Six hub genes, SYP, SYN1, RAB3A, SLC17A7, SYN2, and STXBP1, were consistently identified across all algorithms. All six genes were significantly downregulated in glioma, as confirmed by GEO datasets (area under the curve [AUC]: 0.787-0.802) and clinical qRT-PCR validation. GSEA revealed that low expression of these genes was associated with activation of the cell cycle, complement and coagulation cascades, and immune dysregulation. Immune infiltration analysis showed negative correlations with M1/M2 macrophages and activated natural killer (NK) cells. Single-cell analyses indicated that these hub genes were primarily enriched in tumor-propagating cell (TPC)-like tumor cells but were markedly reduced in glioma core regions. Competing endogenous RNA (ceRNA)/TF networks and drug enrichment analyses suggested multilayered regulatory mechanisms and associations with neurotransmitter-related compounds.

The six identified hub genes are consistently downregulated in glioma and exhibit strong diagnostic potential. Their close association with the immune microenvironment and tumor-cell lineage highlights their value as biomarkers and potential therapeutic targets.

论文信息

作者
Jiang X、Gui Y、Yang Y、Li J、Liang A
第一作者单位
Department of Neurosurgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, 92 Aiguo Road, Donghu District, Nanchang, Jiangxi Province, 330006, China.China
通讯作者单位
Department of Neurosurgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, 92 Aiguo Road, Donghu District, Nanchang, Jiangxi Province, 330006, China. 22251881@qq.com.China
期刊
BMC cancer2025 Dec 13
原文标识
PubMed 41388523 · DOI 10.1186/s12885-025-15454-5